Ambroxol trial started in 2022. 60 participants. Italy

[Little_apple]

clinicaltrials.gov/ct2/show...

GBA1 mutations reduce the enzymatic function of GCase,

[jeffreyn]

Montreal? All 3 "locations" are in Italy.

Currently recruiting PwPs who are Heterozygous carriers of a GBA1 mutation.

[Little_apple in reply to jeffreyn]

corrected

[Little_apple]

*** according to small Israeli study, GCase role is minimized. *** which says to me that Ambroxol might not have the benefit hopes for

there were no significant associations between GCase activity and the risk of Parkinson’s disease. There also were no significant associations found between enzyme activity and various disease symptoms.“GCase activity does not seem to hold promise as a biomarker for disease risk or severity” in Parkinson’s, the researchers concluded, though they noted that interactions between GCase activity and other factors might still have relevance to the development and progression of the disease.The researchers noted that this study has several limitations, including its relatively small size and the fact that patients were only assessed at one point in time.

parkinsonsnewstoday.com/new...